Entrada Therapeutics (Nasdaq: TRDA) reports Q2 2026 results and sets DMD, DM1 data timeline
Rhea-AI Filing Summary
Entrada Therapeutics reported second quarter 2026 results and outlined multiple upcoming clinical milestones across its Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) programs. Cash, cash equivalents and marketable securities were $223.0 million as of June 30, 2026, versus $295.7 million as of December 31, 2025, and the company expects this to fund operations into the third quarter of 2027.
For Q2 2026, collaboration revenue was $0.9 million, R&D expenses were $35.4 million, G&A expenses were $10.5 million, and net loss was $42.8 million, or $1.01 per share. The company highlighted progress in its ELEVATE-44-201, ELEVATE-45-201 and ELEVATE-50-201 DMD studies, plans to advance ENTR-601-51, and ongoing development of VX-670 with Vertex, with multiple data readouts expected between the second half of 2026 and the first half of 2027.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Cash, cash equivalents and marketable securities: $223.0 million
Collaboration revenue Q2 2026: $0.9 million
R&D expenses Q2 2026: $35.4 million
+4 more
7 metrics
Cash, cash equivalents and marketable securities
$223.0 million
As of June 30, 2026; expected to fund operations into the third quarter of 2027
Collaboration revenue Q2 2026
$0.9 million
For the second quarter of 2026, compared to $2.0 million for the same period in 2025
R&D expenses Q2 2026
$35.4 million
For the second quarter of 2026, compared to $37.9 million for the same period in 2025
G&A expenses Q2 2026
$10.5 million
For the second quarter of 2026, compared to $10.9 million for the same period in 2025
Net loss Q2 2026
$42.8 million
For the second quarter of 2026, compared to $43.1 million for the same period in 2025
Net loss per share Q2 2026
$1.01
Basic and diluted net loss per share for the second quarter of 2026, versus $1.04 in 2025
Total stockholders’ equity
$233,411 thousand
Balance sheet data as of June 30, 2026
Key Terms
multiple ascending dose, Time to Rise, Long-Term Extension (LTE), Clinical Trial Authorization, +2 more
6 terms
multiple ascending dose medical
"global Phase 1/2 multiple ascending dose (MAD) portion of the clinical study"
A multiple ascending dose is a method used in testing new medicines where small groups of people receive gradually larger amounts of the drug over time. This approach helps researchers find the safest and most effective dose without causing too many side effects. For investors, it signals ongoing steps in drug development that can impact a company's potential success or approval prospects.
Time to Rise medical
"Cohort 1 data also demonstrated early functional benefits in Time to Rise (TTR)"
Long-Term Extension (LTE) medical
"A Long-Term Extension (LTE) platform study protocol (ENTR-DMD-202) was accepted"
A long-term extension (LTE) is an additional period after an initial clinical study during which participants continue to be monitored for safety and lasting effects of a treatment. For investors, LTEs matter because they produce more reliable data about a drug’s durability, side effects, and real-world value, which can change expectations for regulatory approval, market adoption, revenues, and ongoing development costs — like keeping a product on a longer test drive to see how it performs over time.
Clinical Trial Authorization regulatory
"The Company has completed Clinical Trial Authorization (CTA)-enabling studies"
A clinical trial authorization is official government permission to begin testing an experimental drug or medical device in people; think of it as a building permit that lets researchers move from planning into real-world testing. For investors, receiving this authorization reduces regulatory uncertainty, unlocks fundraising and milestone payments, and starts a clear timeline of studies whose results can greatly affect a company’s value.
myotonic dystrophy type 1 medical
"clinical-stage program, VX-670, for myotonic dystrophy type 1"
A genetic, progressive disorder that causes muscle stiffness, weakness and a range of problems in other body systems (such as breathing, heart rhythm, vision and cognition); symptoms can vary widely and often worsen over time. For investors, it matters because its chronic, multisystem nature shapes the size of the potential patient population, the complexity and cost of clinical trials, regulatory requirements, and long-term demand for any effective treatments — think of it as a condition that requires multiple pieces to be fixed, not just a single part.
Usher syndrome type 2A medical
"ENTR-801, for the potential treatment of Usher syndrome type 2A (USH2A)"
A genetic disorder caused by mutations in the USH2A gene that leads to congenital or early-onset hearing loss and progressive vision loss from retinal degeneration. Think of it like a faulty wiring problem that affects both the ear and the eye over time. It matters to investors because it defines a specific patient population, clinical trial targets and regulatory pathways for therapies, which affect market opportunity and risk for biotech and drug developers.
Earnings Snapshot
Collaboration revenue: $0.9 million for Q2 2026
quarter ended June 30, 2026
Collaboration revenue
$0.9 million for Q2 2026
compared to $2.0 million for the same period in 2025
R&D expenses
$35.4 million for Q2 2026
compared to $37.9 million for the same period in 2025
G&A expenses
$10.5 million for Q2 2026
compared to $10.9 million for the same period in 2025
Net loss
$42.8 million for Q2 2026
compared to $43.1 million for the same period in 2025
Net loss per share
$1.01 basic and diluted for Q2 2026
compared to $1.04 for the same period in 2025
Cash runway
Cash, cash equivalents and marketable securities of $223.0 million
expected to fund operations into the third quarter of 2027
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were Entrada Therapeutics (TRDA) key financial results for Q2 2026?
Entrada reported a net loss of $42.8 million for Q2 2026, or $1.01 per share. Collaboration revenue was $0.9 million, with R&D expenses of $35.4 million and G&A expenses of $10.5 million for the quarter.
How much cash does Entrada Therapeutics (TRDA) have and what is its runway?
Entrada reported $223.0 million in cash, cash equivalents and marketable securities as of June 30, 2026. Based on current operating plans, the company believes this cash will fund operations into the third quarter of 2027.
What clinical milestones did Entrada Therapeutics (TRDA) guide to for its DMD programs?
Entrada expects ELEVATE-45-201 Cohort 1 data in October 2026, ELEVATE-44-201 Cohort 1 open-label data by year-end 2026, and ELEVATE-44-201 Cohort 2 data in the first quarter of 2027, with additional cohorts to follow if needed.
What is the status of Entrada Therapeutics (TRDA) collaboration program VX-670 for DM1?
Vertex has completed enrollment and continues dosing in the GALILEO Phase 1/2 trial of VX-670 in people with DM1. Vertex plans to complete dosing and report Phase 1/2 data in the second half of 2026.
What progress has Entrada Therapeutics (TRDA) made on ENTR-601-44 and ENTR-601-45?
For ELEVATE-44-201, Cohort 2 enrollment is complete, with earlier Cohort 1 showing favorable safety and early functional benefits. For ELEVATE-45-201, Cohort 1 dosing is complete, Cohort 2 is dosing at 10 mg/kg, and multiple data readouts are expected through H1 2027.
How did Entrada Therapeutics (TRDA) operating expenses trend in Q2 2026 versus Q2 2025?
R&D expenses were $35.4 million in Q2 2026 compared to $37.9 million in Q2 2025, and G&A expenses were $10.5 million versus $10.9 million, reflecting modest decreases primarily from lower personnel, facility and professional services costs.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 5, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||
| (Address of principal executive offices) | (Zip Code) | |||||||
Registrant’s telephone number, including area code: (857) 520-9158
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On August 5, 2026, Entrada Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
The following exhibit relating to Item 2.02 of this Form 8-K shall be deemed to be furnished and not filed:
99.1 | Press Release issued by Entrada Therapeutics, Inc. on August 5, 2026 | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | ||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Entrada Therapeutics, Inc. | ||||||||
| Date: August 5, 2026 | /s/ Dipal Doshi | |||||||
| Dipal Doshi | ||||||||
| Chief Executive Officer | ||||||||
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 --
-- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 --
-- Company to report ELEVATE-45-201 Cohort 1 data in October 2026 --
-- ELEVATE-45-201 Cohort 2 dosing ongoing at the increased dose of 10 mg/kg with data expected in H1 2027 --
-- Vertex to report VX-670 Phase 1/2 data in people living with DM1 in H2 2026 --
BOSTON, August 5, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business updates.
“With multiple data readouts ahead in 2026, we are well positioned to deliver on important clinical milestones and further demonstrate the potential of our DMD franchise," said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics. "We are entering a catalyst-rich period with several near-term clinical data readouts including ELEVATE-45-201 Cohort 1 in October 2026, ELEVATE-44-201 Cohort 1 open-label period by year-end 2026 and ELEVATE-44-201 Cohort 2 data in the first quarter of 2027. These data are expected to further characterize the safety, tolerability and emerging functional profile of ENTR-601-44 and ENTR-601-45. Together, with the continued progress of VX-670 through our collaboration with Vertex on DM1, these milestones have the potential to further strengthen the clinical and strategic value of our pipeline as we work to bring transformative new treatment options to people living with serious neuromuscular diseases.”
Recent Corporate Highlights
Clinical-Stage Development Pipeline: Entrada continues to advance multiple clinical programs in people living with Duchenne muscular dystrophy (DMD) in the U.K., EU and U.S., complementing the ongoing clinical progress of its myotonic dystrophy type 1 (DM1) partnership (VX-670) with Vertex.
•ELEVATE-44-201: Enrollment complete for Cohort 2 of the global Phase 1/2 multiple ascending dose (MAD) portion of the clinical study of ENTR-601-44 in ambulatory participants living with DMD who are amenable to exon 44 skipping. Previously announced data from Cohort 1 achieved the primary objective of favorable safety and tolerability, with no discontinuations and no serious adverse events. Cohort 1 data also demonstrated early functional benefits in Time to Rise (TTR) and Time to Rise velocity versus placebo. A Long-Term Extension (LTE) platform study protocol (ENTR-DMD-202) was accepted by U.K and European authorities. ENTR-DMD-202 will enable study participants continued access to ENTR-601-44 and provide for the collection of longer-term safety and efficacy data, including functional measures. The Company is on track to report data from the Cohort 1 (6 mg/kg) open-label period of the study by year-end
2026. The open-label period of the study will assess longer-term safety, continued changes in TTR and other functional measures that are normally assessed in DMD clinical studies. Additional data from Cohort 2 MAD (12 mg/kg) is expected in the first quarter of 2027 and data from Cohort 3 (up to 18 mg/kg) will follow, if needed.
•ELEVATE-44-102: Based on a review of safety, pharmacokinetic and pharmacodynamic data from Cohort 1 of the ELEVATE-44-201 study in the U.K. and EU, the Company plans to re-engage with the FDA to discuss increasing the planned starting dose in this clinical study. The Company will provide an update on clinical study design and timing following interactions with the FDA.
•ELEVATE-45-201: The Company has completed enrollment and dosing of Cohort 1 of the global Phase 1/2 MAD clinical study of ENTR-601-45 in ambulatory participants living with DMD who are amenable to exon 45 skipping. An independent Data Monitoring Committee (DMC) reviewed all available safety and PK data from the eight participants enrolled in Cohort 1 and recommended initiation of Cohort 2 at the increased dose of 10 mg/kg without any protocol modification. All participants from Cohort 1 have transitioned into the open-label, Phase 2 portion of the study. Cohort 2 dosing at 10 mg/kg is ongoing. The Company expects to report data from the Cohort 1 MAD (5 mg/kg) in October 2026, data from the Cohort 2 MAD (10 mg/kg) in the first half of 2027, and data from Cohort 3 (up to 15 mg/kg) will follow, if needed.
•ELEVATE-50-201: The Company received regulatory authorization from the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee to initiate a Phase 1/2 MAD clinical study of ENTR-601-50 in ambulatory participants living with DMD who are amenable to exon 50 skipping. The Company expects to submit additional global regulatory applications following a review of data from the ongoing studies of its lead programs.
•ENTR-601-51: The Company has completed Clinical Trial Authorization (CTA)-enabling studies for people living with DMD who are amenable to exon 51 skipping, which is the largest sub-population of exon-skipping amenable patients. The Company expects to submit global regulatory applications following a review of data from the ongoing studies of its lead programs.
•VX-670: Vertex has completed enrollment and continues dosing in the MAD portion of the GALILEO global Phase 1/2 clinical trial of VX-670 in people with DM1. The study is assessing safety and preliminary efficacy, including change from baseline in the splicing index and other endpoints evaluating muscle function and strength. Vertex is on track to complete dosing and report results in the second half of 2026.
Expanding Preclinical Pipeline: The Company has generated compelling preclinical data from programs focused on ocular and metabolic diseases. The pipeline includes the advancement of two novel oligonucleotide-based programs for the potential treatment of inherited retinal diseases, where there exists high unmet need. The Company announced its first ocular candidate, ENTR-801, for the potential treatment of Usher syndrome type 2A (USH2A) and plans to announce a second clinical candidate in ocular disease in the second half of 2026. The Company will provide additional details on its clinical development strategy at that time.
Upcoming Investor Conferences
•Cantor Global Healthcare Conference, New York, NY on September 9, 2026
Second Quarter 2026 Financial Results
Cash Position: Cash, cash equivalents and marketable securities were $223.0 million as of June 30, 2026, compared to $295.7 million as of December 31, 2025. The decrease was primarily driven by cash used to fund operations. Based on current operating plans, the Company believes that its cash, cash equivalents and marketable securities as of June 30, 2026 will be sufficient to fund its operations into the third quarter of 2027.
Collaboration Revenue: Collaboration revenue was $0.9 million for the second quarter of 2026, compared to $2.0 million for the same period in 2025.
Research & Development (R&D) Expenses: R&D expenses were $35.4 million for the second quarter of 2026, compared to $37.9 million for the same period in 2025. The decrease was primarily driven by lower personnel and facility costs, partially offset by additional expenses incurred related to the Company’s DMD programs.
General & Administrative (G&A) Expenses: G&A expenses were $10.5 million for the second quarter of 2026, compared to $10.9 million for the same period in 2025. The decrease was primarily driven by lower professional services costs.
Net Loss: Net loss was $42.8 million for the second quarter of 2026, compared to $43.1 million for the same period in 2025.
Patients and Their Care Partners
Patients and their care partners are a critical part of our community, and we are committed to keeping them informed and connected. To receive community updates in real time and read today’s quarterly update, please visit Community Updates on our corporate website.
Patients and their care partners are a critical part of our community, and we are committed to keeping them informed and connected. To receive community updates in real time and read today’s quarterly update, please visit Community Updates on our corporate website.
About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.
Forward-Looking Statements
This press release contains express and implied forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Entrada’s strategy, future operations, prospects and plans, objectives of management, the validation and differentiation of Entrada’s approach and EEV platform and its ability to provide a potential treatment for patients, the timing and achievement of anticipated clinical, regulatory and development milestones, expectations regarding Entrada’s Phase 1/2 MAD clinical study of ENTR-601-44, including the potential of the open-label period of the study to assess
longer-term safety and additional functional measures, the potential of the LTE study and its ability to enable continued access to ENTR-601-44 for study participants and provide for the collection of longer-term safety and efficacy data, including functional measures, the timing of data from the Cohort 1 open-label period by year-end 2026 and Cohort 2 in the first quarter of 2027 with data from Cohort 3 to follow, if needed, expectations regarding the initiation of the planned ELEVATE-44-102 study in the U.S., including Entrada’s plans to re-engage with the FDA to discuss increasing the planned starting dose for the study and to provide an update on the clinical study design and timing following such planned interactions, the ability to recruit for and complete the global Phase 1/2 clinical studies of ENTR-601-44, ENTR-601-45, ENTR-601-50 and ENTR-601-51, the potential therapeutic benefits of Entrada’s EEV product candidates, including the potential for ENTR-601-44 to be a transformative treatment option, expectations regarding Entrada's Phase 1/2 MAD clinical study of ENTR-601-45, including the timing of data from Cohort 1 in October 2026 and Cohort 2 in the first half of 2027, with Cohort 3 to follow, if needed, expectations regarding regulatory filings and authorizations and the timing of initiation of the planned clinical studies of ENTR-601-50 and ENTR-601-51, including Entrada’s evaluation of the optimal timing for initiating such studies, the ability to advance therapeutic candidates in indications beyond neuromuscular disease, including but not limited to ocular disease, expectations regarding the timing of announcement of a second clinical candidate for ocular disease and Entrada’s clinical development strategy therefore in the second half of 2026, and the continued development and advancement of ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51 for the treatment of DMD and ENTR-801 for the potential treatment of Usher syndrome type 2A and the partnered product candidate VX-670 for the potential treatment of DM1, expectations regarding the progress and success of Entrada’s collaboration with Vertex, including the timing of Vertex completing dosing and reporting results from the MAD portion of the global Phase 1/2 study of the VX-670 program in the second half of 2026, the ability to continue to expand and develop additional therapeutic programs and modalities, including further exon skipping programs, and the sufficiency of its cash resources for at least twelve months from the date of issuance of the condensed consolidated financial statements for the six months ended June 30, 2026, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Entrada may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities and the initiation and completion of preclinical studies and clinical studies; uncertainties as to the availability and timing of results from preclinical and clinical studies; the timing of and Entrada’s ability to submit and obtain regulatory clearance and initiate clinical studies; whether results from preclinical studies or clinical studies will be predictive of the results of later preclinical studies and clinical studies; whether Entrada’s cash resources will be sufficient to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Entrada’s filings with the Securities and Exchange Commission (SEC), including the Company’s most recent Form 10-K and in subsequent filings Entrada may make with the SEC. In addition, the forward-looking statements included in this press release represent Entrada’s views as of the date of this press release. Entrada anticipates that subsequent events and developments will cause its views to change. However, while Entrada may elect to update
these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Entrada’s views as of any date subsequent to the date of this press release.
ENTRADA THERAPEUTICS, INC.
Condensed Consolidated Statements of Operations (Unaudited)
(In thousands, except share and per share amounts)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Collaboration revenue | $ | 898 | $ | 1,950 | $ | 1,773 | $ | 22,508 | |||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Research and development | 35,369 | 37,877 | 68,423 | 69,951 | |||||||||||||||||||
| General and administrative | 10,492 | 10,922 | 20,616 | 21,196 | |||||||||||||||||||
| Total operating expenses | 45,861 | 48,799 | 89,039 | 91,147 | |||||||||||||||||||
| Loss from operations | (44,963) | (46,849) | (87,266) | (68,639) | |||||||||||||||||||
| Other income: | |||||||||||||||||||||||
| Interest and other income | 2,235 | 3,924 | 4,859 | 8,365 | |||||||||||||||||||
| Total other income | 2,235 | 3,924 | 4,859 | 8,365 | |||||||||||||||||||
| Loss before provision for income taxes | (42,728) | (42,925) | (82,407) | (60,274) | |||||||||||||||||||
| Provision for income taxes | 35 | 178 | 73 | 178 | |||||||||||||||||||
| Net loss | $ | (42,763) | $ | (43,103) | $ | (82,480) | $ | (60,452) | |||||||||||||||
| Net loss per share, basic and diluted | $ | (1.01) | $ | (1.04) | $ | (1.96) | $ | (1.47) | |||||||||||||||
Weighted-average common shares outstanding, basic and diluted | 42,221,665 | 41,338,752 | 42,030,035 | 41,206,974 | |||||||||||||||||||
ENTRADA THERAPEUTICS, INC.
Condensed Consolidated Balance Sheet Data (Unaudited)
(In thousands)
| June 30, | December 31, | ||||||||||
| 2026 | 2025 | ||||||||||
| Cash, cash equivalents and marketable securities | $ | 223,005 | $ | 295,698 | |||||||
| Total assets | $ | 298,877 | $ | 377,378 | |||||||
| Total liabilities | $ | 65,466 | $ | 71,245 | |||||||
| Total stockholders’ equity | $ | 233,411 | $ | 306,133 | |||||||
Investor Contact
Doug Snow
Head of Investor Relations
dsnow@entradatx.com
Patient Advocacy Contact
Sarah Friedhoff
Head of Patient Advocacy
patientadvocacy@entradatx.com
Media Contact
Megan Prock McGrath
CTD Comms, LLC
megan@ctdcomms.com